Thu, December 1, 2022
Wed, November 30, 2022
Tue, November 29, 2022

Mayank Mamtani Maintained (ARWR) at Strong Buy with Decreased Target to $59 on, Nov 30th, 2022

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-59-on-nov-30th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication
Mayank Mamtani of B. Riley Securities, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy with Decreased Target from $65 to $59 on, Nov 30th, 2022.

Mayank has made no other calls on ARWR in the last 4 months.



There are 5 other peers that have a rating on ARWR. Out of the 5 peers that are also analyzing ARWR, 2 agree with Mayank's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Andrew Galler of "Morgan Stanley" Maintained at Hold with Decreased Target to $37 on, Tuesday, November 29th, 2022
  • Mani Foroohar of "SVB Leerink" Maintained at Hold with Decreased Target to $31 on, Tuesday, November 29th, 2022


These are the ratings of the 3 analyists that currently disagree with Mayank


  • Maury Raycroft of "Jefferies" Maintained at Strong Buy with Decreased Target to $75 on, Tuesday, November 29th, 2022
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Decreased Target to $64 on, Thursday, November 10th, 2022
  • Madhu Kumar of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $65 on, Monday, August 8th, 2022